istock-485508035-alexandrumagurean
alexandrumagurean / iStockphoto.com
13 September 2018Big Pharma

LSIPR webinar: HGF delves into personalised healthcare patents

Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

More on this story

Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

More on this story

Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.